Emergent Health Corp signed a letter of intent to acquire Nanosthetic Corp. on January 26, 2023. The transaction is subject to due diligence, negotiation of definitive agreements, and a commitment after closing of funding to purchase equipments and construction of the cleanroom.

Nanosthetic Corp. a biologics company that manufacturers products sold and marketed by Emergent subsidiary Evolutionary Biologics. The combined entities intend to operate a Cleanroom after obtaining FDA clearance for products providing the ability to do clinical trials, testing, and creation of pharmaceutical grade products.

As of February 8, 2023, the company expects to close the acquisition well before the end of February this year. As of February 23, 2023, Emergent Health Corp announced that it will be closing the acquisition on March 1, 2023